Investors

Press Releases

Press Releases

Press Releases

May 05, 2022
Kymera Therapeutics to Share Novel Preclinical Findings Reinforcing the Advantage of IRAK4 Degraders over Kinase Inhibitors as well as First STAT3 Degrader Results in a Preclinical Model of Th17 Inflammation
-Data to be shared at the American Association of Immunologists (AAI) Annual Meeting -Results highlight potential for IRAK4 degraders to broadly impact TLR/IL-1R-driven inflammatory and autoimmune diseases in a manner superior to kinase inhibitors -Findings support further exploration of STAT3
PDF Version
Apr 08, 2022
Kymera Therapeutics Presents Preclinical Data Highlighting Biological Superiority of MDM2 Degradation over Inhibition and Shares Profile of Clinical Candidate KT-253 at the American Association for Cancer Research (AACR) Annual Meeting 2022
MDM2 degradation demonstrated differentiated biological activity and superior cell killing compared to small molecule inhibition in p53 wild-type tumors and led to tumor regressions in xenograft models of ALL and AML KT-253 is a highly potent and selective heterobifunctional MDM2 degrader whose
PDF Version
Displaying 11 - 20 of 20

Investor Contact

Bruce Jacobs, CFA, MBA
Chief Financial Officer
investors@kymeratx.com

Christopher F. Brinzey
Westwicke, an ICR Company for Kymera Therapeutics
chris.brinzey@westwicke.com 
+ 1 339.970.2843
 

Media Contact

media@kymeratx.com

Tyler Gagnon
Director, Corporate Communications
tgagnon@kymeratx.com

Sign Up for Email Alerts